Laurus Labs Limited
LAURUSLABS
Rank in Stocks
#1739
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited,... Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
Share Price
$22.83
Last synced: 2026-10-19
Market Cap
$12.34B
Change (1 day)
0.51%
Change (1 year)
117.95%
Country
IN
Trade Laurus Labs Limited (LAURUSLABS)
Category
Healthcare
P/E ratio for Laurus Labs Limited (LAURUSLABS)
P/E ratio as of October 2026 TTM: 100.45
According to Laurus Labs Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 100.45. At the end of 2024 the company had a P/E ratio of 136.45.
P/E ratio history for Laurus Labs Limited from 2013 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 100.45 | 11.37% |
| 2025 | 90.20 | -33.90% |
| 2024 | 136.45 | 584.38% |
| 2023 | 19.94 | -47.92% |
| 2022 | 38.28 | 94.14% |
| 2021 | 19.72 | 45.26% |
| 2020 | 13.57 | -69.76% |
| 2019 | 44.89 | 39.70% |
| 2018 | 32.13 | 30.85% |
| 2017 | 24.56 | -15.80% |
| 2016 | 29.16 | -32.80% |
| 2015 | 43.40 | 43.54% |
| 2014 | 30.23 | -31.70% |
| 2013 | 44.27 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -65.20% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.